Johnson & Johnson announces new analyses from Phase 3 MARIPOSA study

Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT plus LAZCLUZE significantly reduces the development of epidermal growth factor receptor, EGFR, – and MET-driven resistance compared with osimertinib in patients with EGFR-mutated non-small cell lung cancer, NSCLC, with exon 19 deletion or L858R mutations. These resistance data build on the combination’s previously reported and unmatched overall survival benefit in a chemotherapy-free regimen, which is projected to exceed four years, one year beyond the median observed with osimertinib, and underscore its potential to change the biology of the disease by preventing acquired resistance.2,3 Late-breaking results are being presented at the International Association for the Study of Lung Cancer, IASCL, 2025 World Congress on Lung Cancer, WCLC.